The economic value of screening haemodialysis patients for methicillin-resistant Staphylococcus aureus in the USA

Clinical Microbiology and Infection

Volumn 17, Issue 11, 2011, Pages 1717-1726

  Lee, B Y ^a,b,c   Song, Y ^a,b,c   Mcglone, S M ^a,b,c   Bailey, R R ^a,b,c   Feura, J M ^a,b,c   Tai, J H Y ^a,b,c   Lewis, G J ^a,b,c   Wiringa, A E ^a,b,c   Smith, K J ^d   Muder, R R ^e   Harrison, L H ^f   Piraino, B ^g  

^a Public Health Computational and Operations Research (PHICOR)   (United States)

^b SCHOOL OF MEDICINE   (United States)

^c GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d Section of Decision Sciences and Clinical Systems Modeling   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f Infectious Diseases Epidemiology Research Unit   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness; Economics; Haemodialysis; Methicillin resistant Staphylococcus aureus; Surveillance

Indexed keywords

CHLORHEXIDINE; PSEUDOMONIC ACID; RIFAMPICIN;

ADULT; AGAR DIFFUSION; AGED; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM IDENTIFICATION; COMPUTER MODEL; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; UNITED STATES;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 80054080451     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03525.x     Document Type: Article

References (21)

1. Johnson LB, Jose J, Yousif F, Pawlak J, Saravolatz LD. Prevalence of colonization with community-associated methicillin-resistant Staphylococcus aureus among end-stage renal disease patients and healthcare workers. Infect Control Hosp Epidemiol 2009; 30: 4-8.
2. Centers for Disease Control and Prevention (CDC). Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients-United States, 2005. MMWR 2007; 56: 197-199.
3. Lu PL, Tsai JC, Chiu YW et al. Methicillin-resistant Staphylococcus aureus carriage, infection and transmission in dialysis patients, healthcare workers and their family members. Nephrol Dial Transplant 2008; 23: 1659-1665.
4. National Institutes of Health. United States renal data system. 2009 Annual data report. Bethesda, MD: National Institutes of Health, 2009.
5. Bloom BS, Fendrick AM, Chernew ME, Patel P. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients: a decision analysis. Am J Kidney Dis 1996; 27: 687-694.
6. McConeghy KW, Mikolich DJ, LaPlante KL. Agents of the decolonization of methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2009; 29: 263-280.
7. Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin resistance. Clin Infect Dis 2009; 49: 935-941.
8. Lowrie EG, Li Z, Ofsthun N, Lazarus JM. Measurement of dialyzer clearance, dialysis time, and body size: death risk relationships among patients. Kidney Int 2004; 66: 2077-2084.
9. National Kidney Foundation, Kidney Disease Outcome Quality Initiative (KDOQI) Advisory Board. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (suppl 2): s1-s246.
10. Galland R, Traeger J, Arkouche W, Cleaud C, Delawari E, Fouque D. Short daily hemodialysis rapidly improves nutritional status in hemodialysis patients. Kidney Int 2001; 60: 1555-1560.
11. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Mak 2002; 22: 290-308.
12. Thompson SG, Nixon RM. How sensitive are cost-effectiveness analyses to choice of parameter distributions? Med Decis Mak 2005; 25: 416-423.
13. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff 2000; 19: 92-109.
14. Gorwitz RJ, Kruszon-Moran D, McAllister SK et al. Changes in prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. J Infect Dis 2008; 197: 1226-1234.
15. Lee BY, Tsui BY, Bailey RR et al. Should vascular surgery patients be screened preoperatively for methicillin-resistant Staphylococcus aureus? Infect Control Hosp Epidemiol 2009; 30: 1158-1165.
16. Lee BY, Wiringa AE, Bailey RR et al. Screening cardiac surgery patients for MRSA: an economic computer model. Am J Manag Care 2010; 16: e163-e173.
17. Lee BY, Wiringa AE, Bailey RR et al. The economic effect of screening orthopedic surgery patients pre-operatively for methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol 2010; 31: 1130-1138.
18. Lee BY, Bailey RR, Smith KJ et al. Universal methicillin-resistant Staphylococcus aureus (MRSA) surveillance for adults at hospital admission: an economic model and analysis. Infect Control Hosp Epidemiol 2010; 31: 598-606.
19. Loeb MB, Main C, Eady A, Walkers-Dilks C. Antimicrobial drugs for treating methicillin-resistant Staphylococcus aureus colonization. Cochrane Database Syst Rev 2003; 4: CD003340.
20. Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R, Pittet D. Randomized, placebo-controlled, double-blind trial to evlauate the efficacy of mupirocin for eradicating carriage of methicillin-resistanct Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 1412-1416.
21. Boelart JR, De Smedt RA, De Baere YA et al. The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. Nephrol Dial Transplant 1989; 4: 278-281.